Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8327818 | 0.96 | GRM5 (0.44) | MAOAMAOBCYP2A6GRM5TDP2 | |
| SCHEMBL31298937 | 0.89 | GRM5 (0.40) | MAOAMAOBCYP2A6GRM5TDP2 | |
| SCHEMBL4015467 | 0.88 | TDP2 (0.45) | MAOAMAOBCYP2A6GRM5TDP2 | |
| SCHEMBL29807425 | 0.88 | TDP2 (0.45) | MAOAMAOBCYP2A6GRM5TDP2 | |
| Quinoline SCHEMBL28061152 | 0.80 | ALDH1A1 (0.44) | MAOAMAOBCYP2A6GRM5MAPT | |
| SCHEMBL829095 | 0.80 | TDP2 (0.52) | MAOAMAOBCYP2A6TDP2NSD2 | |
| SCHEMBL28316531 | 0.76 | CYP19A1 (0.38) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL10072403 | 0.76 | CYP19A1 (0.35) | GRM5TDP2NSD2ABL1PLCG1 | |
| SCHEMBL2715285 | 0.76 | PARP1 (0.46) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL22579802 | 0.75 | TDP1 (0.42) | TDP2NSD2ABL1PLCG1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937348-B1 | PROCESS FOR THE PREPARATION OF A COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP BIOSCIENCES PTE LTD (SG) | 2021-09-08 | — | — | EP | claimed |
| CN-113121497-A | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | 奥瑞基尼探索技术有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-9809589-B2 | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO., LTD. (CN) | 2017-11-07 | — | — | US | claimed |
| CN-105026391-B | Crystal formation of compound as mineralocorticoid receptor antagonists and preparation method thereof | 山东亨利医药科技有限责任公司 | 2016-11-16 | — | — | CN | claimed |
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP BIOSCIENCES CO., LTD. (CN) | 2015-11-26 | — | — | US | claimed |
| CN-105026391-A | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO LTD | 2015-11-04 | — | — | CN | claimed |
| EP-2937348-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP Biosciences Co., Ltd. (CN) | 2015-10-28 | — | — | EP | claimed |
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3703692-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-3933507-A | LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER | AGFA-GEVAERT, A.G. (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | NR3C2, REN, MC2R | MAOA 3698/4885MAOB 3678/4885CYP2A6 156/4885 |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | MAOA 17/4885MAOB 21/4885CYP2A6 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.